Outcomes and Molecular Profile of Oligomonocytic CMML Support its Consideration as The First Stage in the CMML Continuum.

Calvo, X., Roman-Bravo, D., Garcia-Gisbert, N., Rodriguez-Sevilla, JJ., Garcia-Avila, S., Florensa, L., Gibert, J., Fernández-Rodríguez, C., Salido, M., Puiggros, A., Espinet, B., Colomo, L., Bellosillo, B., Ferrer, A., Arenillas, L. (2022). Blood Advances 2022. Aceptado, pendiente de publicación.

Response to azacitidine in patients with chronic myelomonocytic leukemia according to overlap myelodysplastic/myeloproliferative neoplasms criteria

A.TrigueroabdB.XicoybcdL.ZamorabcMJ.JiménezbcdO.GarcíacM.CalabuigbM.Díaz-BeyáabJ.ArzuagabF.RamosbA.MedinabT.BernalbC.TalarnbR.CollbR.ColladobT.HuaChenbJ.BorrásbS.BrunetbI.MarchantebV.MarcobF.López-CadenasbM.CalbachobA.SimielebM.CortésbMT.CedenabM.PedreñobC.AguilarbC.PedróbM.FernándezbC.StoicabJM.RiberacdG.Sanzb. Leukemia Research. Volume 116, May 2022, 106836.

Guiding the Global Evolution of Cytogenetic Testing for Hematologic Malignancies.

Yassmine M.N. Akkari, Linda B. Baughn, Adrian M. Dubuc, Mar Mallo, Adam C. Smith, Paola Dal Cin, Maria Diez Del Campelo, Marta S. Gallego, Isabel Granada Font, Detlef T. Haase, Brigitte Schlegelberger, Irma Slavutsky, Cristina Mecucci, Ross L. Levine, Robert P. Hasserjian, Francesc Solé*, Brynn Levy*, Xinjie Xu**. Blood. PMID: 35167654. IF: 17.543. TIPO PUBLICACIÓN: A.

Pre-leukemic CD34+CD22+CD19- early B-cell progenitors might underlie phenotypic escape in patients treated with CD19-directed immunotherapies.

Clara Bueno, Susana Barrera, Josep María Ribera, Valentín Ortiz-Maldonado, Natalina Elliot, Sorcha O’byrne, Guanlin Wang, Alex Bataller, Montse Rovira, Francisco Gutierrez-Agüera, Juan Luis Trincado, María González, Mireia Morgades, Paloma Bárcena, Samanta R Zanetti, Nerea Vega, Mireia Camós, Mar Mallo, Francesc Sole, Supat Thongjuea, Adam J Mead, Irene Roberts, Manel Juan, Julio Delgado, Alvaro Urbano-Ispizúa, Alberto Orfao, Anindita Roy, Pablo Menéndez. Blood. PMID: xxx. IF. 17.543. TIPO PUBLICACION: A.